ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1941

Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events

Shu Cao1, Caroline Bresnan2, Si Li3, Yichen Wang3 and Yih Chang Lin1, 1University of South Florida, Morsani College of Medicine, Tampa, FL, 2University of South Florida, Morsani College of Medicine, Tampa, 3The Wright Center for Graduate Medical Education, Scranton

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) has been shown to have an increased risk of developing deep venous thrombosis (DVT), pulmonary embolism (PE) and combined thromboembolism (VTE) events in many studies. However, the impact of GCA on hospital stay outcomes in these patients with VTE including mortality, length of stay (LOS) and hospitalization cost is unknown. The aim of this study is to assess whether patients with GCA are experiencing more negative outcomes when compared with the general population during their in-hospital stay for VTE events utilizing the National Inpatient Sample (NIS) database.  

Methods: We conducted a retrospective study on the association between GCA and VTE. Adult patients admitted with a principal diagnosis of DVT or PE were included. GCA patients were identified among these patients if they also carry a diagnosis of GCA on admission. We used data from the NIS database between the period of 2012 to 2014. We used the International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System (ICD-9-CM) to identify co-morbid conditions and in-hospital complications. Multivariate regression analysis via STATA 16.0 was used to examine the association of in-hospital mortality, LOS and cost between GCA and non-GCA patients during their VTE admissions. A p-value of 0.05 was selected as the statistical significance threshold.

Results: We identified 897,180 admissions with VTE, among which 1,010 had GCA. Patients with GCA were older (mean age 78.5 vs. 62.5), more likely to be female (81.2% vs. 52.2%), have Medicare insurance (91.0% vs. 54.4%), chronic kidney disease (21.8% vs. 13.2%), hypertension (70.8% vs. 58.7%) and hyperlipidemia (42.1% vs. 33.0%).  After adjustment of possible confounding variables within the patient and hospital level, there was no statistically significant difference in the in-hospital mortality, LOS, and cost of hospitalization when comparing GCA and non-GCA in VTE admissions (p = 0.752, 0.640, and 0.392, respectively).

Conclusion: GCA patients who were primarily hospitalized for VTE events do not have worse outcomes as compared to non-GCA patients in terms of mortality, LOS or cost of hospitalization. Future research will be warranted to investigate and confirm this finding.


Disclosure: S. Cao, None; C. Bresnan, None; S. Li, None; Y. Wang, None; Y. Lin, None.

To cite this abstract in AMA style:

Cao S, Bresnan C, Li S, Wang Y, Lin Y. Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/outcome-of-giant-cell-arteritis-patients-who-were-primarily-admitted-for-venous-thromboembolism-events/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcome-of-giant-cell-arteritis-patients-who-were-primarily-admitted-for-venous-thromboembolism-events/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology